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Vaccines and the looming threat of syphilis
Charles T. Ambrose*
Department of Microbiology, Immunology, and Molecular Genetics, College of Medicine, University of Kentucky, USA
Abstract
During the past several decades, syphilis has increased in the US and explosively so in China and Russia. While most current cases can be cured by penicillin or 
second line antibiotics, strains of the syphilis spirochete (Treponema pallidum) resistant to the latter have emerged. And the potential of strains to acquire resistance 
to penicillin via plasmids has recently been recognized. The 36 million-plus undertreated cases of syphilis in the world represent metaphorically a vast global 37°C 
incubator allowing exchange of antibiotic resistant genes among the human-borne bacteria and theoretically permitting the emergence of penicillin resistant strains. 
None has yet been identified but they seem inevitable along with the threat of multi-resistant strains.
There is now concern over the lack of new antibiotics to succeed the penicillins. Since such new drugs would likely require a decade or so of research and federal 
approval, vaccine-based protection is of immediate consideration here. This approach may exploit the new knowledge about the biology of T. pallidum strains their 
many complex antigens, serotypes, and the latter’s distribution in populations. Equally important are recent insights into immunology, such as cellular aspects and 
antigenic competition.
Introduction
While the prevalence of syphilis in the United States has nearly 
tripled over the past decade or so, this disease may present an even 
greater threat to public health in the future [1]. During the past two 
decades in China there has been 30-fold increase in syphilis and in 
Russia nearly a 70-fold increase. If this ‘explosive resurgence’ abroad 
continues and spreads throughout the world, in time it might lead 
to the emergence of strains of the syphilis spirochete (Treponema 
pallidum) resistant to penicillin, which has been the standard therapy 
for the infection since the 1940s. Such deadly strains would eventually 
reach this country. Resistance to antibiotics (including to penicillin) 
is present in many bacteria and is transferred among them by genetic 
means discussed later. Conditions for the appearance of resistant 
strains of syphilis to penicillin and other ‘back-up’ antibiotics are 
especially optimal globally with so many millions of untreated persons 
harboring multi-drug resistant bacteria. Clinicians are worried about 
the current absence of new antibiotics to treat many newly resistant 
human pathogens [2].
This essay reviews briefly the global increase of venereal syphilis 
and discusses the genetic basis of potential penicillin resistance in T. 
pallidum (Sections 2 & 3). During the mid-19th century, vaccines were 
sought for syphilis unsuccessfully, but a century later they seemed 
unnecessary with the advent of effective antibiotics. However, today 
with the theoretical threat of antibiotic-resistant syphilis emerging and 
in the current absence of new successor antibiotics, there is revived 
interest in vaccines for syphilis. 
Treponemal pallidum causes venereal syphilis. Milder, non-
venereal, cutaneous infections are produced by other closely related 
treponemal species/strains, such as yaws, pinta, and bejel (Sec. 4). The 
genetic relationship among these five pathogens is treated here. New 
information about treponemal surface antigens is reviewed next (Sec. 
5). Genetic typing of T. pallidum has revealed that multiple strains are 
prevalent in a human community at any one time. These may compete 
with one another during a given luetic infection (Sec. 6 & 8). How to 
exploit this newer knowledge in devising a vaccine is the challenge at 
hand. 
The recent resurgence of syphilis (Lues venerea)
In the US before the Second World War, syphilis was estimated 
to have infected 5% to 10% of the US general population and 25% of 
impoverished groups especially those in southern states. In 1937, US 
Surgeon General Thomas Parran (1892-1968) had called syphilis the 
“shadow on the land” [3]. In 1947 the overall prevalence was 66/100,000 
but declined dramatically after penicillin became available in the mid-
1940s to the level of 2.1/100,000 by 2000 [4]. However, during the so 
called ‘sexual revolution’ it rose to 5.5/100,000 by 2013 with 9.3/100,000 
in men [1]. A striking example of this increase was the epidemic in San 
Francisco, where the prevalence was 3.8/100,000 in 1999 and rose to 
26/100,000 in 2007 [5] (Table 1). 
In China the disease was reported to have been largely eradicated 
(<2/100,000) in the 1960s by aggressive public health policies of the 
government. But in recent years there has been an “explosive return 
of the Great Pox” a 25-fold increase from the early 1990s to 2007 
and a further 5-fold increase through 2011 [6-8]. The incidence rose 
to 8.71/100,000 in 2005 throughout the country and to 32/100,000 in 
2011. It was much higher in many cities e.g., 77/100,000 in Shanghai 
in 2008 [9]. The one-child policy of the Communist government and 
female-weighted abortions in families led to an excess of unmarried 
males and accounted for the rise in MSM (male-sex-male) venereal 
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infections [7]. Migration into crowded cities promoted spread of the 
disease (Table 1).
In Russia, the collapse of its health system during the 1990s has led 
a similar rise in syphilis and other infectious diseases for syphilis from 
4/100,000 in 1988 to 263/100,000 in 1996 [10]. In St. Petersburg the 
prevalence was 318/100,000 in 1995 [11] (Table 1).
Throughout the world, according to recent estimates, syphilis 
infects 36 million persons and is newly acquired each year by 11 
million more. It causes over 100,000 deaths in spite of penicillin being 
considered an effective cure for nearly all current luetic infections [12-
14] (Table 1).
Penicillin and T. pallidum
Since the mid- 1940s, the standard therapy for syphilis has involved 
various forms of penicillin agents containing a critical β-lactam ring. 
Syphilitics allergic to penicillin have been treated with second-line 
antibiotics e.g., macrolides (azithromycin, erythromycin, spiramycin) 
and tetracyclines (doxycycline, etc.) [15]. However, strains of T. 
pallidum resistant to these second-line antibiotics have appeared an 
example being azithromycin resistance, which was found in 77.3% of 
the T. pallidum specimens isolated in 2006 in San Francisco [5]. 
To date, no penicillin-resistant strains of T. pallidum have been 
reported, but they seem inevitable. The 36 million-plus people infected 
with T. pallidum represent a global microbial pool capable of spreading 
the syphilis among their billion neighbors. Each person (infected or 
not) is a 37°C incubator harboring in the GI tract and elsewhere a 
vast array of bacteria which interact with one another notably in 
transferring genetic information via plasmids. These are small pieces 
of DNA containing genes, including some coding antibiotic resistance. 
For example, strains of Neisseria gonorrhoeae acquired resistance 
to penicillin and its derivatives via plasmids encoding β-lactamase 
activity which came from ampicillin-resistant strains of Haemophilus 
influenzae [16]. The enzyme β-lactamase, inactivates penicillin by 
disabling its essential β-lactam ring. 
Surprising and disturbing to siphilologists was the discovery in 
1981 that plasmids exist in T. pallidum, thus indicating that it has the 
potential to acquire resistance to penicillin by genetic mechanisms 
frequently used by other bacteria [17,18]. One such example is a strain 
of Klebsiella pneumoniae (an enteric organism) containing an enzyme 
which breaks down carbapenem (a β-lactam antibiotic like penicillin 
G). The gene for this enzyme is contained in a plasmid, which can 
move from K. pneumoniae to other bacteria (e.g., T. pallidum). This 
condition represents “a risk as serious as terrorism” [19]. 
The ultimate therapeutic threat would be strains of T. pallidum 
exhibiting resistance to all forms of penicillin and also to backup 
antibiotics. The medical literature is filled with other examples 
of multiple drug resistance i.e., in staphylococci, enteric bacilli, 
Mycobacterium tuberculosis, etc. [20]. The World Health Organization 
and other public health agencies have declared antibiotic resistance to 
be the greatest threat to global public health [21]. A multiple resistant 
strain of T. pallidum seems likely to appear somewhere and enter the US 
population, facilitated by the international travel of infected persons. 
A growing concern here is that the “developmental pipeline 
(for new antibiotic agents) is empty” because many drug companies 
have found this area unprofitable, focusing instead on drugs treating 
common chronic diseases. Roche “fled the field in 1999.” Eli Lilly 
“dropped its antibiotic research in 2002,” and other companies joined 
them in abandoning the area [22]. The continued emergence of drug-
resistant bacteria has prompted the US government “to coax companies 
back to the field,” but the productive momentum they once had may 
take years to regain. 
While new anti-syphilitic drugs would be aggressively sought by 
the pharmaceutical industry in the event of an epidemic of a resistant 
strain, there is no great pressure to do so in advance of the therapeutic, 
commercial demand. Meanwhile, alternate treatments need be 
considered, such as vaccines. Recent discoveries in the immunology 
and genetics of the treponemes, extending also to those species/
subspecies of this genus causing non-venereal diseases, may help devise 
an effective vaccine. 
Treponemal diseases in the world
Siphilologists have been conflicted over relationships among the 
various treponemal pathogens accounting for four related diseases seen 
throughout the world venereal syphilis, yaws, pinta, and bejel (endemic 
syphilis). All these treponemes are morphologically identical and 
closely related serologically. All currently are suppressed by penicillin 
but produce different pathologies, which are summarized below. It’s 
uncertain whether there is any protective cross-reaction among the 
four agents, but some reciprocal immunity may exist between yaws and 
syphilis as judged by the latter’s relative absence in areas with a high 
prevalence of yaws [23,24].
Venereal syphilis (VS, lues venerea) elicits genital lesions (chancres) 
initially and later affects various organ systems as ‘tertiary sequelae’ 
in around 30% of untreated cases. In contrast, three non-venereal 
treponemal infections produce conspicuous lesions on the exposed 
parts of the body but no significant constitutional/systemic symptoms 
(i.e., no chills, fever, weight loss, etc.) and no later organ involvement. 
 1947 1956 1988 1995 1996 1999 2000 2005 2007 2008 2011 2013
USA 66 3.9    2.1     5.5  
Men            9.3
San Francisco        3.8  26   
China  <2     8.7   32   
Shanghai         77    
Russia   4  263        
St. Petersburg    318         
Finland    2         
Table 1.  Global Prevalence of Syphilis per 100,000 Population.
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Yaws (Y) occurs in warm humid rural areas of Africa, SE Asia, and the 
Americas and causes multiple granular papillomas on unclothed legs, 
arms, and the face of children mainly. Pinta (P) is present primarily in 
South/Central America and causes dry scaly lesions on exposed skin. 
Bejel (B) is found in the dry, warm Middle East, and in severe cases 
may produce gummatous ulcerative lesion on the face. Bejel in Europe 
is also termed endemic syphilis. The latter two (P, B) are characterized 
also by moist papules in the axilla and skin folds and mucous patches 
in the mouth.
The characteristic clinical pictures produced by T. palllidum and 
the non-venereal treponemes reflect the particular tissue tropism of 
the respective infecting species/strains i.e., area of the body primarily 
affected (tropism, Gr. = ‘turning’ to some area). The non-venereal 
treponemes infect mainly the skin and mouth but not the warmer 
internal organs of the body. For example, unlike venereal syphilis, 
neither yaws, pinta, nor bejel produces neurological sequelae nor are 
they transmitted from an infected mother to her foetus [23]. 
Strain differences may also account for the various clinical pictures 
seen during late/tertiary stages of venereal syphilis i.e, gummatous 
bony lesions, cardiovascular pathology, or neurological involvement. 
One particular strain has been found more often in persons with 
neurosyphilis than in other syphilitics, again suggesting subspecies 
tropism [24,25].
Medical historians have speculated on how these subtypes evolved 
and how lues venerea entered into Europe during the mid-1490s. The 
Columbian theory proposes that this virulent disease arose from a 
non-venereal treponeme in the Americas and was imported from the 
Caribbean by infected sailors returning from Columbus’ first voyage 
there. Other theories attribute decaying matter or animals in Africa as 
the origin of non-venereal treponemes which subsequently infected 
people and spread via them to the Americas and Europe, ultimately 
producing lues venerea. Endnote #1 summarizes such speculations by 
three investigators which link the various treponemal strains from an 
evolutionary standpoint [28-30]. 
K.N. Harper et al. provided scientific support for the Columbian 
theory of syphilis’ entrance into Europe from America based on 
DNA analyses. This group sequenced select gene regions of twenty-
six geographically dispersed strains of pathogenic treponemes and 
concluded that strains causing venereal syphilis now resemble 
phylogenetically yaws strains from South America [31]. These studies 
lead logically to a review of treponemal antigens, strain typing, and 
distribution of the many T. pallidum strains. 
Antigens and strain typing of T. pallidum subspp. 
pallidum 
Subspecies and strain differences reflect in part the complex 
array of spirochetal surface antigens. Treponemes have a fragile outer 
membrane and a more stable inner one. The former contains unstable 
antigenic determinants coded by twelve T. pallidum repeat genes 
(Tpr). Different strains express different combinations of Tpr proteins 
[32]. The inner membrane contains several lipoprotein antigens (e.g., 
TpN47, TpN17, etc.), which are accessible for expression only when 
the outer membrane is disrupted or aged. Adding to this complexity 
is the fact that within one particular antigen (TprK) are seven discrete 
variable regions coded by different alleles [33]. The relative importance 
of these different antigens in producing protective immunity is unclear 
at present, but progress has begun in distinguishing different strains. 
Allen Pillay and colleagues developed a method for typing strains 
of T. pallidum [34]. Intrastrain variability is exhibited by two genes a 
member of the T. pallidum repeat (tpr=Tpr) gene family and the acidic 
repeat protein (arp) gene. The method involves isolating both genes 
from a sample, amplifying them by polymerase chain reaction, and 
analyzing the products of endonuclease digestion. More than 40 strain 
types have been identified (e.g., 14a, 14d, 15a, etc.) and many subtypes 
(12df, 14d9, etc.).
Subsequent studies using this new technique have shown that many 
different strains (up to 16 or so) are present during the same period in 
a given large urban areas [35]. For example, during 1999-2008, strain 
type 14d9 represented 53% of the 4 different strains recovered from 69 
of persons in San Francisco and 51% of the 8 found in Seattle [5,36]. 
Strain type 14a comprised 54% of the 4 different strains found in 
Pretoria and 50% of the 3 in Lisbon [36]. Thus different sexual partners 
in a community may harbor different strains. To date, so far as I am 
aware, only one strain has been identified in a given individual, but 
this may reflect not having examined numerous samples from the same 
person and perhaps not early enough.
Luetic infections clearance vs. reduction = cure vs. 
protection 
Although lacking confirmation, one current supposition is that a 
given syphilitic may harbor initially several strains of T. pallidum – 
i.e., genetically different subpopulations, each with a wide repertoire 
of antigens [37]. This diversity could come about in two ways. 1) 
contacts with different sexual partners would allow the introduction of 
several different strains from the different ‘spirochetal donors’. 2) New 
antigenic subtypes might also arise de novo by mutations of spirochetes 
present in an individual. 
During the month or so after a person becomes infected from one or 
more sexual partners and while the immune response is being engaged, 
many or most of the acquired treponemes are assumed to be cleared, 
but one or more may persist to produce clinical manifestations [38,39]. 
Of the several concurrent infecting strains of T. pallidum, those with 
stronger or more accessible antigen may produce a ‘robust’ immune 
response and be eliminated by opsonic antibodies/phagocytosis and 
delayed-type immunity, while the ‘weaker’ strain/s would evoke a 
lesser response, might escape immune surveillance, and thus survive 
in the host to produce disease [32]. Whether immunological tolerance 
might develop to this ‘survivor’ strain is a consideration. Cullen and 
Cremer have made a distinction between protection from the disease 
(nonsterile immunity due merely to reduced spirochetal numbers) and 
complete clearance of the organism (sterile immunity) [40]. 
The following is a plausible ‘strain’ history for an untreated 
syphilitic, but this scenario has not yet been validated by typing studies. 
In a given person, an early reduction in strain varieties from immune 
surveillance may be offset by new strains acquired during later sexual 
contacts or possibly by mutations in stains already present. Thus the 
initial repertoire of treponemal strains in that person may change over 
time. 
Studies on syphilis ‘vaccination’ past and recent 
Philippe Ricord (1800-1889), the famous French venereologist, 
advocated ‘vaccinating’ against syphilis in a long series of letters to 
the Editor of the Union Médicale of Paris, 1850-51. (Endnote#2) 
Syphilologists then distinguished between indurated (hardened) 
and non-indurated chancres and believed that multiple inoculations 
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with the “virulent pus” from the latter over many months could be a 
“prophylaxis against constitutional syphilis” (tertiary sequellae) much 
as vaccinia from cowpox pustules protects people from smallpox [41]. 
A contentious issue at that time was how many sequential contacts 
with chancre fluid/pus were needed to ‘induce immunity’ up to a 
score or more, some maintained. Proof of immunity for the French 
investigators then seemed to be merely the later absence of signs of 
secondary or tertiary syphilis.
Interest in immunizing for syphilis resumed a century later with 
investigators who sought to obtain non-infectious strains by heating 
isolates or using other procedures. Their negative results were likely 
due to labile surface antigens being destroyed in the process. The 
first limited success was obtained in 1969 by Metzer et al. In earlier 
studies these investigators had established the protein nature of the 
immunizing antigens and next sought to attenuate/reduce strain 
virulence by storage at 4°C for 7-10 days. They used a Nichols strain 
of T. pallidum to vaccinate rabbits by IV injections 4-times/week for 7 
weeks [42]. Some of the rabbits showed “a high degree of immunity” 
upon challenge with infectious treponemes i.e., no lesions/chancres 
appeared at the inoculating sites in the skin. But spirochetes were 
still latent in the treated rabbits i.e., “sterile immunity” had not been 
achieved.
In later, more successful immunization studies, James N. Miller 
sought to preserve labile surface antigens by using a γ-irradiated, now 
non-infectious Nichols strain. He administered this preparation to 
rabbits IV daily over a 37-week period and found them “completely 
resistant to intradermal challenge (with homologous treponemes) 
administered 10 days after the last immunizing injection” [43]. 
Protection persisted for one year. There was minimal immunity to 
challenge with T. pertenue, the agent of yaws thus indicating specificity 
for venereal syphilis.
The 37-week long injection protocol in rabbits would not be 
practical in human subjects. In any case, the prospect for successful 
immunization is complicated by the possibility that several strains of 
T. pallidum may infect a given person at the same time. Whether each 
impedes or influences the immune responses (and the elimination) of 
others is an issue examined next. 
Antigenic competition 
Differences in the immune responses of several concurrently 
infecting T. pallidum strains are likely due to the ‘strength’ of their 
presenting antigens, but another influence might be that of antigenic 
competition, as explained next. Immunization with two antigens 
given together (or within days of each other) elicits separate immune 
responses for both, but the level of each response is lower with paired 
stimulation than when either antigen is given alone. In other words, two 
antigen introduced together limit reciprocally somewhat the response 
of each other. There is considerable variability here, depending on the 
type of the antigens, the doses, the timing of each stimulus, etc. The 
nature of this competition was the subject of scores of research papers 
and reviews in the 1970s [44,45].
My studies in this area then involved lymph node organ cultures 
prepared from rabbits primed months earlier with two antigens e.g., 
bovine serum albumin and diphtheria toxoid. Each culture consisted of 
a dozen 1 mm3 size lymph node fragments bathed in 1 ml of a chemically 
defined medium [46]. Incubating the cultures with the antigens on Day 
0 for two hours elicited the secondary antibody responses to both, 
which continued over a month as measured in the medium replaced 
every three days. Pooled lymph nodes from a single primed rabbit 
provides 60-100 culture tubes, thus allowing many variables (each 
in 4 or more replicate tubes) to be examined in one experiment e.g., 
detailed dose response effects. The individual responses were measured 
in the culture medium by hemagglutination titration assays. 
The antigenic competition demonstrated in this culture system 
was not due to some limiting nutritional factor [47]. Related to this 
phenomenon was the surprising observation that very low levels of 
certain antibiotics enhanced antibody production in these cultures. For 
example, adding increasing levels of chloramphenicol or actinomycin 
D during the inductive phase of the in vitro response (Days 0-6), 
produced the expected dose response inhibition during the subsequent 
productive phase (Days 6-30+). However, extremely low levels of these 
same agents included after Day 6 cause a paradoxical increase in the 
antibody responses [46,48].
This observation led to the isolation and characterization of an 
‘antibody inhibitory material’ (AIM) released in the spent medium 
[48,49]. The highest inhibitory effect was found in medium recovered 
on Day 6, 9, & 12 of the 18-day culture period. I postulated that the 
paradoxical increase was due to AIM-containing cells producing 
less AIM because of their being more sensitive to the low levels of 
actinomycin D than the antibody secreting cells. Other investigators 
also identified such inhibitory factors (cytokines) and termed them 
‘suppressor’ factor/s i.e., products of so-called ‘suppressor’ cells (Ts). A 
decade later, ‘T regulatory cells’ (Treg) became the preferred term [50].
More recently, Tregs have been hypothesized these to be of two types 
one is specific for a given antigen, while another is ‘non-specific’ the 
latter presumably being involved in antigenic competition [50,51]. 
Examining this phenomenon in terms of antibody production, allergy, 
and autoimmunity has been the subject of numerous reviews during 
the past several decades [50-54]. Relevant to the subject of syphilis 
is whether the multiple antigens of one spirochete strain infecting a 
person exert antigenic competition with other introduced strains.
A ‘classical’ immunization approach has employed a ‘mild’ 
live organism related to a major pathogen in order elicit protective 
immunity against the latter e.g., M. bovis for M. tuberculosis and cowpox 
or vaccinia virus for the variola virus. Perhaps a relatively ‘mild’ strain 
of T. pallidum (like one of the non-luetic treponemes) could be isolated 
and used as a live vaccine for syphilis seeking to protect against the 
more virulent strains. As noted before, there is a “relative absence of 
venereal syphilis in areas with a high prevalence of yaws” [23,24]. 
Vaccines and the two forms of immunity
The focus of a vaccine for syphilis has evolved over the past decade 
or so. Initially, it has been eliciting a protective humoral response 
(opsonic antibodies) in order to eliminate T. pallidum via phagocytosis. 
For example, in 2006 Cullen and Cameron discussed various T. 
pallidum vaccines whole cell, subunit, and non-protein carbohydrate 
antigens, which might mediate ‘opsonophagocytosis’ [40].
A seminal paper in 2011 by Carlson et al. viewed the clinical course 
of syphilis as being determined by the balance between delayed type 
hypersensitivity (DTH) and humoral immunity to T. pallidum. The 
authors argued that a strong DTH clears organisms initially from 
the body, while a strong humoral response later leads to “prolonged 
infection and progression to tertiary disease” [55]. They concluded 
that a potential vaccine for syphilis should be directed towards the 
developing the DTH response. This could be enhanced by including 
BCG in the vaccine. 
Ambrose CT (2015) Vaccines and the looming threat of syphilis
Glob Vaccines Immunol, 2016         doi: 10.15761/GVI.1000104  Volume 1(1): 8-13
Finally, in 2014, Cameron and Lukehart emphasized that a 
successful vaccine should involve both the DTH response and opsonic 
antibodies/phagocytosis [56]. Thus currently, there seems no consensus 
for making an effective vaccine.
Summary
The theoretical threat of a multi-resistant strain of T. pallidum 
appearing in the near future is compounded by the current absence of 
new antibiotics effective against this putative new pathogenic strain. 
Indeed, this therapeutic void prompted a recent article entitled as 
a question “A return to the pre-antimicrobial era?” [57]. These two 
linked concerns provided an excuse to review here new information 
about syphilis (e.g., treponemal antigens, serotyping, etc.) and old 
relevant studies (e.g., P. Ricord’s ‘vaccinations’, antigenic competition). 
Syphilis therapeutics for over a century has been wedded to the 
concept of a ‘magic bullet’ (magische Kugel) which kills infecting 
spirochetes. Modification of some past ‘cure’ might include, for 
example, improvement in heavy metal therapy. Fever therapy was 
effective in relieving the signs and symptoms in some persons with 
neurosyphilis. A review of pre-antibiotic anti-syphilitic treatments has 
been submitted elsewhere. But the other important defense against 
most infections is the host’s immune response. Developing a vaccine 
for syphilis will build on the new information about the biology of 
T. pallidum strains and their immunology. Special consideration 
must be given to the two competing modalities of immunity humoral 
(opsonization) and cellular (DTH).
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Endnotes
1. Theories on the Origin of Various Treponemal Types
E.H. Hudson (1961) postulated that the treponemal group arose 
in Africa from spirochetes growing on decaying vegetable matter [26]. 
In the beginning, a strain appeared which thrived on the exposed 
skin of natives, producing the clinical picture of yaws (Y). Around 
100,000 years ago their infected descendants migrated to other parts 
of the world (including the Americas), where a new strain, pinta (P), 
emerged. In the warm areas of the Middle East, bejel (B) evolved and 
later spread north. In dry, often cold Europe, where clothing was worn, 
the spirochete could only survive and spread via the moist genital 
organs, producing a mild infection called endemic syphilis (ES). 
Hudson did not explain how virulent venereal syphilis (VS) appeared 
there around 1494. 
C.J. Hackett (1963) proposed a comparable evolution of the 
treponemes with the difference that that the progenitor of the four 
was pinta, which crossed over from an animal infection to people 
about 15,000 BC [27]. It originated in Africa, reached the Americas, 
and many millennia later spawned yaws there. From pinta in Africa 
arose bejel, which entered Europe in a mild form (endemic syphilis, ES) 
beginning in the first century BC. It changed abruptly to the virulent 
venereal syphilis (VS) near the end of the fifteenth century. 
The evolutionary scenarios of Hudson and Hackett both favor the 
Old World origin for the emergence of venereal syphilis in Europe. 
R.S. Morton (1968) advanced a variation in this story: namely, in 
the later 1490s, morbus gallicus involved “two disease existing side-
by side” – the mild endemic syphilis (ES from Africa) long present 
in Europe and a yaws strain newly introduced from America which 
evoked an acute illness in the Europeans [28]. For several decades, the 
severe Columbian (Y) strain dominated as virulent syphilis (VS), but 
later the milder African strain (ES) became the prevalent one. 
2. Philippe Ricord was born in Baltimore of parents who fled there 
from the French Revolution. During his professional career in Paris, 
Ricord become the leading physician treating venereal diseases. He is 
most famous for establishing that syphilis and gonorrhea are distinct 
diseases thus correcting the confusion in this subject created by John 
Hunter’s flawed self-inoculation experiments.
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